HLX208 (Not yet branded)

Description

HLX208 is a BRAF V600E inhibitor specifically developed for the treatment of metastatic colorectal cancer harboring the BRAF V600E mutation. This targeted therapy is designed to selectively block the mutated BRAF protein that drives tumor growth in approximately 8-10% of colorectal cancer patients. HLX208 has been evaluated both as monotherapy and in combination with cetuximab for patients with BRAF V600E-mutated metastatic colorectal cancer who have progressed after first-line treatment.

Mechanism of Action

HLX208 works by selectively inhibiting the BRAF V600E mutant kinase, which is part of the RAS/RAF/MEK/ERK signaling pathway that regulates cell proliferation and survival. The BRAF V600E mutation leads to constitutive activation of this pathway, promoting uncontrolled cancer cell growth. By blocking this mutated protein, HLX208 disrupts the aberrant signaling cascade and induces cancer cell death.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials